Redfund Capital Corp. (CSE:LOAN, OTC:PNNRF, Frankfurt:O3X4) (Redfund Capital or the “Company”) is pleased to announce the Company has signed the definitive agreement for an equity stake in the Sunshine State Tea Company (“SSTC”), based in Florida, USA.

Sunshine State Tea’s main product line is tasty infused CBD tea that has been tested to reveal zero percent THC. There are 8 varieties of tea; 4 caffeinated blends and 4 herbal decaffeinated ones. Each 8 tea bundle box has a diverse selection of flavors with 10mg CBD in each tea bag. Sunshine State production is manufactured in Washington State. The tea bags are certified and tested at a third party approved lab facility to authenticate and analyze the milligrams of CBD in the individual bags.

These are the terms of the definitive option agreement signed on February 6, 2020 between Redfund Capital and the Sunshine State Tea Company which supersedes the letter of interest signed in November 2019 between the parties. The Company has agreed to purchase 18% of SSTC with consideration in common shares and has agreed to the valuation of Sunshine State Tea being CDN $1,500,000. The share issuance allotment will reflect current market price at the time of issuance and have a 4 month hold period. The Company will allocate CDN $500,000 in a promissory note towards the project within the first 3 years. Terms of the Note will be disclosed after the signing.

This transaction, which is expected to close shortly, is a non arms-length transaction in that Meris Kott, CEO of Redfund, is an insider of the other party. Redfund is relying on certain valuation and minority approval exemptions from MI 61 -101. Independent members of the board of Redfund have reviewed and approved the transaction.

A Few of Our Portfolio Company Updates from their Management:

Biominerales Pharma Corp. is reporting they are continuing to increase their revenues Stateside. At their Colorado subsidiary, they are processing CBD distillate free from THC from their organic hemp crop and manufacturing a branded product line under the Hempire Farms logo.

RxMM Health Capital Inc. is working with associated company, Clerisy Corporation, of New York, to launch their Alzheimer Defense Product. Its ALZ Defense Gelcaps have already been scientifically tested for Alzheimer Onset Prevention Support.

Wahupta Ventures Inc. is working hard to increase their revenues by building strategic alliances in the hemp-cbd marketplace and extraction sector. They are navigating the stringent due diligence process to the public markets and evaluating the timing for their listing to an approved public exchange.

Mary’s Wellness Ltd. is working with Canadian licensed partners and regulators on their product approval for new lines of their infused beverages with the intent to bring to the Canadian marketplace, new and dynamic forms of their branded classic tea products for consumers. Virginia Vidal, CEO will be speaking on a panel at the O’Cannabiz conference in Toronto on Friday April 24, 2020.

“Redfund Capital has established the first tier of its investment client portfolio during its first fiscal year. The Company’s focus in 2020 will be in developing additional revenue streams with advisory services and joint venture partnerships. Additionally, we are pursuing meaningful acquisitions as part of a new aggressive M&A strategy. Our current loans are in good standing and we are looking forward to expanding our portfolio. This new relationship with Sunshine State Tea was designed to help position Redfund as a player in a well-defined, high-growth niche within the rapidly expanding non THC CBD and hemp sector,” said Meris Kott, CEO.

About Redfund Capital Corp.

Redfund provides debt and equity funding plus advisory services to mid-to-late stages of a target company’s development, or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related, healthcarerelated target companies.

For further information please visit

For more information on Redfund Capital contact

Meris Kott CEO 604.484.8989


Further information about the Company is available on under the Company’s profile.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the Property, financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Click here to connect with Redfund Capital Corporation (CSE:LOAN) for an Investor Presentation.


Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less